Asia Fresh News

Asia Fresh Stories

Archive for April 12th, 2017

CORRECTION – APAC Biotech Pvt. Ltd: Indian FDA Approves the First Autologous Dendritic Cell-based Immuno-oncology Product, APCEDEN(R)

leave a comment »

NEW YORK /PRNewswire/ — A first-of-its-kind Indian biotechnology company, APAC Biotech, was granted with a commercial license by Indian FDA (CDSCO – Central Drugs Standard Control Organization) to market product, APCEDEN®, a Dendritic cell-based autologous Immuno-oncology product for four cancer indication namely Prostate, Ovarian, Colo-rectal and Non Small Cell Lung carcinoma.

The Indian Food and Drug Administration authorities, after their stringent review of the application, have issued the commercial license (Form 46) to conduct a post marketing surveillance on statistically significant number of patients for each indication.

“The past decades have seen revolutionary progress in the development and application of cell and genetic engineering in an effort to personalize the treatment of cancer. We are now confident that it is possible to treat cancer patients using this approach as observed during clinical trials across India. The results are encouraging and mark a potential new paradigm in treating these solid tumors that do not respond to standard therapies,” said a leading oncologist, Dr. Ashok Vaid.

APCEDEN, an autologous monocyte-derived mature Dendritic cell when loaded with tumor antigen have the ability to generate an effective immune response against the tumor. In the year 2011, an ATTEST trial was conducted where refractory solid tumor with multiple chemo failure patients were enrolled and administered with APCEDEN. The results were published in International Journal of Cytotherapy in the year 2014. ATTEST study included a stringent logistics management and was uniquely, effectively, conducted under the leadership of Principal investigator, Medical oncologist, Dr. P P Bapsy.

The trial was designed to understand the potential benefits and risk of the therapy. In the trial 28.9% of cases showed stability of disease with good quality of life. A retrospective study was also conducted on the advice of CBBTDEC (Cell Biology Based Therapeutic Drug Evaluation Committee), ICMR (Indian Council of Medical Research) where more than 200 days’ of survival benefit was observed as compared to the retrospective control group.

About APAC Biotech

http://www.apacbiotech.com
Media Contact:
Dr. Bandana Sharan
drbandana@apacbiotech.com

Source: APAC Biotech Pvt. Ltd

Written by asiafreshnews

April 12, 2017 at 3:17 pm

Posted in Uncategorized

Mundipharma Announces Strategic Partnership with Kolon Life Science to Market Invossa(TM) in Korea

leave a comment »

-Hailed as world’s first cell-medicated gene therapy for osteoarthritis
-Strategic marketing partnership to ensure reach to surgeons, hospitals and GPs
-Korean market partnership as a potential forerunner for global marketing expansion

SINGAPORE /PRNewswire/ — Mundipharma has announced a strategic partnership with Kolon Life Science to market InvossaTM, which has been hailed as the world’s first cell-medicated gene therapy for osteoarthritis1, expected to be approved by the Korean Ministry of Food and Drug Safety (MFDS), in the second quarter of 2017.

InvossaTM is an intra-articular injection that is non-surgical treatment option. Demonstrating sustained pain reduction and functional improvement of articular joint for two years following a single injection in clinical trials2,3.

Under the terms of the partnership, Mundipharma will be responsible for the marketing and distribution of InvossaTM to general and semi-private hospitals, while Kolon Pharma will take responsibility for the general practitioner market. InvossaTM is exported globally by Mitsubishi Tanabe.

“Mundipharma is attracted to strategic partnerships that extend our ability to respond to patient needs in specific markets as well as improving treatment outcomes globally,” said Raman Singh, CEO, Mundipharma. “This partnership levers the strength of our network capability and experience to ensure that hospitals, GPs and patients are informed and supported in the introduction of this new breakthrough treatment of osteoarthritic pain in Korea and beyond.”

The Osteoarthritis Research Society International (OARSI) defines osteoarthritis (OA) as ‘a disorder involving movable joints characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses including pro-inflammatory pathways of innate immunity4.

Korea has an estimated five million patients requiring access to orthopaedic treatments every year, says Woo-Sok Lee President and CEO, Kolon Life Sciences. “Mundipharma is wellrespected in the orthopaedic and neurosurgical community and has proven sales and marketing capabilities in the area of pain management and advanced wound dressing products in markets worldwide.

“They are an ideal partner to help establish InvossaTM in Korea and worldwide as we look to scale InvossaTM as a global standard treatment option.”

1

http://kolonls.web31.youhost.co.kr/eng/02business/bio02.php

2

A placebo controlled, double-blind, randomized, parallel-group, multi-center phase III study to determine the efficacy and safety of tissue-gene C in patients with degenerative osteoarthritis, Protocol No. KS-TGC-01-3. CSR v1.0. 2016 (data is not published yet)

3

A phase II study to determine the efficacy and safety of allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. Protocol No. TGC09201. CSR. 2015 (data is not published yet)

4

OARSI. Definition of osteoarthritis. 2015 (cited 2015 18 November 2015). http://oarsi.org/research/standardization-osteoarthritis-definitions

About InvossaTM

InvossaTM is composed of a 3:1 mixture of normal human chondrocytes (hChonJ) and human chondrocytes transduced with the human TGF-B1 gene (hChonJb#7). The hChonJb#7 cells are irradiated prior to dosing to render them replication incompetent. InvossaTM polarize macrophage to M2 macrophage. M2 macrophage has immune-regulatory function by producing Interleukin-10. Therefore, InvossaTM reduce pain and improve articular immune environment contribute to self-recovery of articular joint.

About Kolon Life Science

Kolon Life Science has been developing innovative cell and gene therapies including Invossa, the world’s first cell-mediated gene therapy for osteoarthritis, since its founding in 2000. In addition to its biopharmaceuticals business, the company is also engaged in the business of providing active pharmaceuticals ingredients (API), eco-chemicals including antimicrobials for personal-care and industrial applications, as well as water-treatment solutions.

For more information, please visit www.kolonls.co.kr/eng.

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg.

Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO

Source: Mundipharma

Written by asiafreshnews

April 12, 2017 at 11:39 am

Posted in Uncategorized

TransUnion Offers Free Access of Credit Data

leave a comment »

HONG KONG /PRNewswire/ — TransUnion (NYSE: TRU) today announced it will offer consumers a seven-day free trial beginning in April 2017 to celebrate the launch of Debt Analysis and Score Trending, new features designed to educate Hong Kongers about credit.

Recognizing a need for better credit comprehension and management, TransUnion, a global leader in information and risk management, has enhanced features included with its subscription product that give consumers context around their credit report, clear direction for improving scores and more.

From now on, consumers can experience unlimited access to their credit data for free as part of a seven-day trial.

“We are pleased to offer this free trial to Hong Kong people,” said Lawrence Lo, Director, Consumer Interactive for TransUnion Hong Kong. “Credit scoring plays a critical role in our major life decisions, from securing a job to buying a home. With our mission of ‘Information for Good’, we believe our service can provide practical information for users to make their life-changing decisions better and smarter.”

The features build upon TransUnion credit report service, providingconsumers with a credit score and summarizing an individual’s credit history and activities. It measures borrower riskiness, which is commonly used by banks and financial institutions in Hong Kong and across the globe when evaluating credit applications and lending conditions, such as interest rates and repayment terms, be it for credit cards, personal loans or even mortgages.

Features of free trial include:

  • Credit Score & Score Factors. Credit Score ranges between A and J, where A is the highest score. It is a snapshot of your financial status. Score Factors provides a summary of the rationale behind your credit score. It gives users direction on how to improve their score going forward, providing valuable tips for maintaining credit health around the clock.
  • Debt Analysis. Users can enjoy a detailed view of their current debt to better understand where they stand in their credit. By entering the monthly income and expenses, TransUnion will calculate the debt-to-income (DTI) ratio for users to conveniently manage their budget. Debt Analysis captures and synchronizes the debt record listed in the credit report whenever they refresh the credit data.
  • Score Trending. As credit score changes over time, Score Trending helps to monitor how users’ credit has progressed throughout the year once activated. It is a powerful tool to assess flaws within the history and how to improve upon them.
  • Credit Alerts. TransUnion’s Credit Alerts feature warns users whenever there are changes to their credit accounts so they can react immediately whenever anything suspicious occurs, thereby mitigating the potential damage done by identity thieves.

“We strongly advise all Hong Kongers to check their credit score frequently and regularly as everyone has the responsibility to understand their own credit status as part of successful financial management,” said Mr. Lo. “One should also see this as a financial health check in case the credit score is incorrectly presented which might have consequences for lending capability. We hope this free trial campaign can bring more public attention to the importance of maintaining credit health.”

You can learn more about the features and how to enroll in a free trial by visiting transunion.hk.

About TransUnion (NYSE: TRU)

Information is a powerful thing. At TransUnion, we realize that. We are dedicated to finding innovative ways information can be used to help individuals make better and smarter decisions. We help uncover unique stories, trends and insights behind each data point, using historical information as well as alternative data sources. This allows a variety of markets and businesses to better manage risk and consumers to better manage their credit, personal information and identity. Today, TransUnion has a global presence in more than 30 countries and a leading presence in several international markets across North America, Africa, Latin America and Asia. Through the power of information, TransUnion is working to build stronger economies and families and safer communities worldwide.

We call this Information for Goodtransunion.hk

For more information, please contact:

Weber Shandwick Hong Kong
Juliana Li / Winky Chow
jli2@webershandwick.com / wchow@webershandwick.com
2533 9973 / 2533 9923

Written by asiafreshnews

April 12, 2017 at 11:03 am

Posted in Uncategorized

Global Alternator Market Fuelled by Power Demand-supply Gap, Industrialisation Boom in Emerging Markets, and New Technologies

leave a comment »

Established firms can acquire smaller players and invest in developing nations to expand opportunities, finds Frost & Sullivan’s Power Generation team

LONDON /PRNewswire/ — The global alternator market is driven by a rising demand for energy efficiency and security, technology advancements, and power demand-supply gap. Growing industrialization in the Asia-Pacific region, the shift toward renewable power generation, and investment in distributed energy will drive market revenues to $5.19 billion by 2020. In a highly fragmented market dominated by relabels, alternator suppliers must look to integrate with power generation original equipment manufacturers (OEMs) to increase revenues, reduce costs, and improve product quality.

“Technology advancements such as the optimisation of speed, eco technology, and customisable solutions are increasing the popularity of distributed energy and fuelling the growth of the global alternator market. To capture these opportunities, power generation OEMs are looking toward enhancing electromechanical performances, increased control, remote monitoring features and applicability in renewable power generation,” said Frost & Sullivan Energy & Environment Programme Manager Pritil Gunjan.

Global Alternator Market, Forecast to 2020, new analysis from Frost & Sullivan’s Power Generation Growth Partnership Service program, includes an in-depth analysis of the alternator market with a specific focus on growth rate by region, applications, competitive landscape, and future focus for key market players such as Leroy Somer, Cummins, ABB, Mecc Alte, Marathon, and other.

To know more about Frost & Sullivan’s research and to sign up for our Growth Strategy Dialogue, a complimentary one-hour interactive session with Frost & Sullivan’s thought leaders, please go to: https://go.frost.com/forms/PR_ContactUs?PR=AZ&RS=MC7A14

Economic growth, urbanisation, and the need for electrification have spurred alternator market growth in Asia-Pacific countries like China, India, and Japan. These countries will account for more than 50 percent of all alternator sales by 2020 due to high demand from power generation, cogeneration, and industrial sectors. Other alternator developments include:

  • Significant opportunities for alternators in the gas power market due to an increase in renewable power generation and need for flexibility in power generation.
  • OEM focus on procuring standardised products so that lead times are shorter and cost savings can be realized through greater economies of scale.
  • Demand for low-voltage alternators for emergency and back-up power, while industrial and prime power providers adopt high/medium voltage units.

“The alternator market is ripe for further mergers and acquisitions. Established firms should consider acquiring smaller firms to absorb their technology and expand product portfolios and/or invest in firms from developing nations, which will give market access in restricted markets,” noted Gunjan. “Suppliers must identify key challenges and define localization strategies for success in emerging markets.”

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.

Contact:
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://ww2.frost.com

Source: Frost & Sullivan
Related Links:

Written by asiafreshnews

April 12, 2017 at 10:18 am

Posted in Uncategorized